Clinical Trial Update: Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of MCI-186 for amyotrophic lateral sclerosis has completed and results have been posted. The study was sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• MCI-186 (edaravone)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: COMPLETED | Results posted: 2017-12-20